Juan Gómez-Rivas, MD, discusses barriers to PSMA-PET imaging and how disparities in access may affect prostate cancer staging and treatment planning.
|Videos|November 17, 2022
Dr. David Silver discusses his experience with HIFU
Author(s)Urology Times staff
Silver also outlines an example of a patient who he would treat with high-intensity focused ultrasound.
Advertisement
In this video, David A. Silver, MD, shares his experience with high-intensity focused ultrasound (HIFU) and describes a sample case. Silver is chief of urology at Maimonides Medical Center in Brooklyn, New York.
Advertisement
Related to this article
Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.
Martin Schoen, MD, PhD, discusses how clinicians can interpret comparative real-world evidence and indirect analyses when head-to-head ARPI data are unavailable.
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
Isaac Y. Kim, MD, PhD, MBA, joins to discuss the evolving data surrounding neoadjuvant therapy before radical prostatectomy in prostate cancer.
Eugene Cone, MD, discusses SWOG S1602 findings comparing Tokyo-172 and TICE BCG and the potential role of alternative BCG strains in NMIBC
Jonathan Harper, MD, discusses findings from the PUSH trial may inform counseling on hydration and stone recurrence.
Cameron C. Jones, MD, discusses patient selection for Aquablation, including prostate size, anatomy, and factors that may favor alternative BPH procedures.
The study is assessing the safety and preliminary efficacy of CD28 co-stimulation in patients with mCRPC.
Advertisement
Advertisement
Trending on Urology Times
1
FAQs: The 2026 AUA Guideline on Medical Management of Kidney Stones
2
The UroOnc Minute: Neoadjuvant Therapy Before Radical Prostatectomy, With Isaac Y. Kim, MD, PhD, MBA
3
Jonathan Harper, MD, on the importance of fluid intake for reducing stone recurrence
4
Health Canada accepts vibegron submission for overactive bladder
5